Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301
Antonius A. Miller(Roswell Park Comprehensive Cancer Center), Mark J. Ratain(University of Chicago), Richard C. Frank(Memorial Sloan Kettering Cancer Center), Kouros Owzar(Duke University), Fred Millard(Roswell Park Comprehensive Cancer Center), Marwan Fakih(City of Hope), Martin J. Edelman(Fox Chase Cancer Center), Donna Hollis(University of North Carolina at Chapel Hill), Ghassan K. Abou‐Alfa(Memorial Sloan Kettering Cancer Center), Daryl J. Murry(University of Nebraska Medical Center), Erin B. Kennedy(Northwell Health), Jimmy J. Hwang(University of California, San Francisco), Apurva A. Desai(University of Chicago Medical Center), E. Claire Dees(University of North Carolina at Chapel Hill), Raymond J. Hohl(Pennsylvania State University), Lionel D. Lewis(Dartmouth College), Miguel A. Villalona‐Calero(University of California, Irvine)
Cited by 207
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k